Physician profile
Sarah Boice
NPI 1376997510
$3,201.64
in general payments reported to CMS, 2019-2025
33 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $426 · 2023: $917 · 2024: $980 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.36 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $515.52 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $350.25 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $322.14 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $223.23 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $208.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $145.34 | 2024-2025 | Voquezna |
| Abbvie INC. | $140.81 | 2021-2025 | Qulipta, Synthroid |
| Axsome Therapeutics, INC. | $139.93 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $132.15 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Pfizer INC. | $117.84 | 2023-2025 | |
| Abbott Laboratories | $92.42 | 2025 | Freestyle Insulinx, Freestyle Libre 3, Proclaim |
| Currax Pharmaceuticals LLC | $75.16 | 2023-2025 | Contrave, Onzetra Xsail, Nexlizet |
| Takeda Pharmaceuticals U.S.A., INC. | $64.67 | 2021-2024 | Trintellix |
| Sanofi Pasteur INC. | $61.30 | 2021-2024 | |
| Baxter Healthcare | $58.42 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.41 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $51.90 | 2022-2025 | Nuzyra |
| Dexcom, INC. | $48.73 | 2023-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $42.66 | 2022-2023 | Unithroid |
| Lundbeck LLC | $37.09 | 2022-2024 | Rexulti |
| Amgen INC. | $36.77 | 2024 | Repatha, Otezla |
| Ibsa Pharma INC. | $36.43 | 2025 | Flector, Licart, Tirosint |
| Cranial Technologies, INC | $34.82 | 2025 | Doc Band |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.61 | 2022-2023 | Xifaxan |
| Eisai INC. | $27.76 | 2024 | |
| Hikma Pharmaceuticals USA | $26.37 | 2023 | Ryaltris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.32 | 2022 | |
| Daiichi Sankyo INC. | $23.60 | 2022 | |
| Seqirus USA INC | $20.92 | 2025 | Flucelvax, Fluad |
| Astellas Pharma US INC | $14.93 | 2023 | Veozah |
| Jazz Pharmaceuticals INC. | $14.30 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.85 | 2022 | |
| Kaleo, INC. | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Boice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.